References of "Beckers, Albert"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailA multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues
Franck, Sanne Elisabeth; Korevaar, Tim; PETROSSIANS, Patrick ULg et al

in European Journal of Endocrinology (2017)

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and ... [more ▼]

Background: Effective treatment of acromegaly with pegvisomant (PEGV), a growth hormone receptor antagonist, requires an appropriate dose titration. PEGV doses vary widely among individual patients, and various covariates may affect its dosing and pharmacokinetics. Objective: To identify predictors of the PEGV dose required to normalize insulin-like growth factor I (IGF-I) levels during PEGV monotherapy and in combination with long-acting somatostatin analogues (LA-SSAs). 188) were meta-analysed as a form of external replication to study the predictors of PEGV dosing in addition to LA-SSA, the LAS (n=83) was used to study the predictors of PEGV monotherapy dosing. Multivariable regression models were used to identify predictors of the PEGV dose required to normalize IGF-I levels. <0.001, p=<0.001, p=0.028 and p=0.047, respectively). Taken together, these characteristics predicted the PEGV normalization dose correctly in 63.3% of all patients within a range of +/- 60 mg/week (21.3% within a range of +/- 20 mg/week). For monotherapy, only weight was associated with the PEGV normalization dose (p=<0.001) and predicted this dosage correctly in 77.1% of all patients within a range of +/- 60 mg/week (31.3% within a range of +/- 20 mg/week). Conclusion: In this study, we show that IGF-I levels, weight, height and age can contribute to define the optimal PEGV dose in order to normalize IGF-I levels in addition to LA-SSA. For PEGV monotherapy, only the patient's weight was associated with the IGF-I normalization PEGV dosage. [less ▲]

Detailed reference viewed: 26 (5 ULg)
Full Text
Peer Reviewed
See detailThe role of AIP mutations in pituitary adenomas: 10 years on
Daly, Adrian ULg; BECKERS, Albert ULg

in Endocrine (2016)

Detailed reference viewed: 23 (5 ULg)
See detailScreening for genetic causes of GH hypersecretion
Rostomyan, Liliya ULg; Beckers, Albert ULg

Conference (2016, November)

Detailed reference viewed: 21 (3 ULg)
See detailThe history of XLAG syndrome (2015)
Beckers, Albert ULg

Scientific conference (2016, November)

Detailed reference viewed: 30 (1 ULg)
See detailApplying new developments in the genetic understanding of inherited pituitary adenoma.
Beckers, Albert ULg

Scientific conference (2016, November)

Detailed reference viewed: 21 (1 ULg)
Full Text
Peer Reviewed
See detailUne hypokaliémie à Liège
VALDES SOCIN, Hernan Gonzalo ULg; EMONTS, Patrick ULg; HAMOIR, Etienne ULg et al

Conference (2016, October 15)

Detailed reference viewed: 42 (1 ULg)
Full Text
Peer Reviewed
See detailProspective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
VROONEN, Laurent ULg; Lancellotti, Patrizio ULg; Garcia, Monica Tome et al

in Endocrine (2016)

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated ... [more ▼]

Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia. We report here a series of 100 patients (71F; median age at diagnosis: 41.5 years) treated with cabergoline for endocrine diseases (prolactinoma n = 89, idiopathic hyperprolactinemia n = 11). All patients underwent complete transthoracic echocardiographic studies at baseline and during long-term prospective surveillance using the same equipment and performed by the same technicians. The median interval between baseline and last follow-up echocardiographic studies while on cabergoline was 62.5 months (interquartile range: 34.75-77.0). The median total duration of cabergoline treatment was 124.5 months (interquartile range: 80.75-188.75) and the median cumulative total dose of cabergoline was 277.8 mg (interquartile range : 121.4-437.8 mg) at last follow-up. We found no clinically relevant alterations in cardiac valve function or valvular calcifications with cabergoline treatment. Our data suggest that findings from retrospective analyses are correct and that cabergoline is a safe chronic treatment at the doses used typically in endocrinology. [less ▲]

Detailed reference viewed: 21 (5 ULg)
Full Text
See detailFaut-il suivre par IRM hypophysaire les patients porteurs de macroprolactinome dont l'hypersécrétion est contrôlée médicalement ?
Eroukhmanoff, J; Tejedor, I; Potorac, Iulia ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 17 (1 ULg)
Full Text
See detailFrom guidelines to real daily practice : prolactinoma in pregnancy
VROONEN, Laurent ULg; Potorac, Iulia ULg; D'Andréa, S et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 16 (1 ULg)
Full Text
See detailA new clinical presentation of a non-so-rare disease, the Di George syndrome
VROONEN, Laurent ULg; D'Andrea, S; Tome, M et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 18 (2 ULg)
Full Text
See detailUtilisation de la cabergoline dans le traitement palliatif de la maladie de Cushing : l'étude Frenchcab
Ferriere, A; Cortet, C; Chanson, P et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 30 (1 ULg)
Full Text
See detailSomatic mosaicism is implicated in the etiology of XLAG syndrome
Rostomyan, Liliya ULg; Daly, Adrian ULg; Yuan, Bo et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 16 (3 ULg)
Full Text
See detailHypogonadism due to a novel inactivating mutation of the luteinizing hormone beta subunit (LHB) gene leading to impaired protein trafficking
Potorac, Iulia ULg; Rivero-muller, a; Trehan, A et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 22 (3 ULg)
Full Text
See detailThyroid nodule : metastasis or primary neoplasm ?
PETIGNOT, Sandrine ULg; PETROSSIANS, Patrick ULg; VAN DAELE, Daniel ULg et al

in 26nd meeting of the Belgian Endocrine Society - Abstract book (2016, October)

Detailed reference viewed: 14 (1 ULg)
See detailThe peroxisome proliferator-activated receptor Alpha (PPARA) is expressed in non-somatotroph pituitary adenomas : a potential therapeutic target ?
Rotondi, S; Polidoro, MA; Morace, R et al

Poster (2016, October)

Detailed reference viewed: 8 (1 ULg)
Full Text
See detailLe syndrome de De Morsier : une cause congénitale méconnue d'hypopituitarisme
VALDES SOCIN, Hernan Gonzalo ULg; VERLOES, Alain ULg; Debray, François-Guillaume ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 13 (3 ULg)
Full Text
See detailMaladie de Cushing et kyste de la poche de Rathke : un défi diagnostique
VROONEN, Laurent ULg; KREUTZ, Julie ULg; Potorac, Iulia ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 17 (3 ULg)
Full Text
See detailHypogonadisme hypogonadotrope anosmique associé à une nouvelle mutation hétérozygote c.937C>T, p.His314Tyr de l'isoforme IIIb du gène FGR1.
VALDES SOCIN, Hernan Gonzalo ULg; CORMAN, Vinciane ULg; LIBIOULLE, Cécile ULg et al

in Annales d'Endocrinologie : 33ème congrès de la Société Française d'Endocrinologie (2016, October)

Detailed reference viewed: 8 (0 ULg)
See detailThe road from the adenoma valley through the forest of genetic testing in pituitary adenoma
Beckers, Albert ULg

Scientific conference (2016, October)

Detailed reference viewed: 14 (1 ULg)